Counterpoint: Long-Course Chemoradiation Is Preferable in the Neoadjuvant Treatment of Rectal Cancer

Seminars in Radiation Oncology

Volumn 21, Issue 3, 2011, Pages 228-233

  Minsky, Bruce D ^a  

^a UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CAPECITABINE; FLUORODEOXYGLUCOSE; FLUOROURACIL; OXALIPLATIN;

ANUS SPHINCTER; CANCER ADJUVANT THERAPY; CANCER CONTROL; CANCER MORTALITY; CANCER RECURRENCE; CANCER REGRESSION; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMORADIOTHERAPY; COMPARATIVE STUDY; CONTINUOUS INFUSION; DIFFUSION WEIGHTED IMAGING; EUROPE; HUMAN; MULTIPLE CYCLE TREATMENT; NORTH AMERICA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECTUM CANCER; REVIEW; SHORT COURSE THERAPY; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; WOUND INFECTION;

CHEMOTHERAPY, ADJUVANT; DOSE FRACTIONATION; EVIDENCE-BASED MEDICINE; HUMANS; LYMPHATIC METASTASIS; NEOADJUVANT THERAPY; NEOPLASM STAGING; PREOPERATIVE CARE; RADIOTHERAPY DOSAGE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECTAL NEOPLASMS; SURVIVAL RATE; TIME FACTORS;

EID: 79958004636     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2011.02.009     Document Type: Review

References (64)

1. Minsky B.D., Welton M., Venook A. Cancer of the rectum. Leibel and Phillips Textbook of Radiation Oncology 2010, 851-869. Elsevier, Philadelphia, PA. R.T. Hoppe, T.L. Phillips, M. Roche (Eds.).
2. Adjuvant therapy for patients with colon and rectal cancer. JAMA 1990, 264:1444-1450. National Institutes of HealthConsensus Conference.
3. Sauer R., Becker H., Hohenberger P., et al. Preoperative chemoradiotherapy as compared with postoperative chemoradiotherapy for locally advanced rectal cancer. N Engl J Med 2004, 351:11-20.
4. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997, 336:980-987. Swedish Rectal Cancer Trial.
5. Folkesson J., Birgisson H., Pahlman L., et al. Swedish rectal cancer trial: Long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005, 23:5644-5650.
6. Kapiteijn E., Marijnen C.A.M., Nagtegaal I.D., et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer. N Engl J Med 2001, 345:638-646.
7. Holm T., Rutqvist L.E., Johansson H., et al. Postoperative mortality in rectal cancer treated with or without preoperative radiotherapy: Causes and risk factors. Br J Surg 1996, 83:964-968.
8. Frykholm G.J., Glimelius B., Pahlman L. Preoperative or postoperative irradiation in adenocarcinoma of the rectum: Final treatment results of a randomized trial and an evaluation of late secondary effects. Dis Colon Rectum 1993, 36:564-572.
9. Francois Y., Nemoz C.J., Baulieux J., et al. Influence of the interval between preoperative radiation therapy and surgery on downstaging and on the rate of sphincter-sparing surgery for rectal cancer: The Lyon R90-01 randomized trial. J Clin Oncol 1999, 17:2396-2402.
10. Bujko K., Nowacki M.P., Nasierowska-Guttmejer A., et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: Report of a randomized trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004, 72:15-24.
11. Bujko K., Nowacki M.P., Nasierowska-Guttmejer A., et al. Long term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006, 93:1215-1223.
12. Ngan S., Fischer R., Goldstein D., et al. A randomized trial comparing local recurrence (LR) rates between short course (SC) and long course (LC) radiotherapy (RT) for clinical T3 rectal cancer: An Intergroup (TROG, AGITG, CSSANZ, RACS). Proc Am Soc Clin Oncol 2010, 28:15s.
13. van Dijk T.H., Havenga K., Beukema J., et al. Short-course radiation therapy, neoadjuvant bevacizumab, capecitabine and oxaliplatin, and radical resection of primary tumor and metastasis in primary stage IV rectal cancer: A phase II multicenter study of the Dutch Colorectal Cancer Group. Proc Am Soc Clin Oncol 2010, 28:295s.
14. Roh M.S., Colangelo L.H., O'Connell M.J., et al. Pre-operative multimodality therapy improves disease-free survival in patients with carcinoma of the rectum (NSABP-R-03). J Clin Oncol 2009, 27:5124-5130.
15. Tepper J.E., O'Connell M.J., Niedzwiecki D., et al. Adjuvant therapy in rectal cancer: Analysis of stage, sex, and local control-Final report of Intergroup 0114. J Clin Oncol 2002, 20:1744-1750.
16. Barbaro B., Valentini V., Coco C., et al. Tumor vascularity evaluated by transrectal color Doppler US in predicting therapy outcome for low-lying rectal cancer. Int J Radiat Oncol Biol Phys 2005, 63:1304-1308.
17. Salerno G.V., Daniels I.R., Moran B.J., et al. Magnetic resonance imaging prediction of an involved surgical resection margin in low rectal cancer. Dis Colon Rectum 2009, 52:632-639.
18. Kim N.K., Kim M.J., Park J.K., et al. Preoperative staging of rectal cancer with MRI: Accuracy and clinical usefulness. Ann Surg Oncol 2000, 7:732-737.
19. Kim Y.H., Kim D.Y., Kim T.H., et al. Usefulness of magnetic resonance volumetric evaluation in predicting response to preoperative concurrent chemoradiotherapy in patients with resectable rectal cancer. Int J Radiat Oncol Biol Phys 2005, 62:761-768.
20. Kuo L.J., Chern M.C., Tsou M.H., et al. Interpretation of magnetic resonance imaging for locally advanced rectal carcinoma after preoperative chemoradiation therapy. Dis Colon Rectum 2005, 48:23-28.
21. Barbaro B., Schulsinger A., Valentini V., et al. The accuracy of transrectal ultrasound in predicting the pathological stage of low-lying rectal cancer after preoperative chemoradiation therapy. Int J Radiat Oncol Biol Phys 1999, 43:1043-1047.
22. Kristiansen C., Loft A., Berthelsen A.K., et al. PET/CT and histopathologic response to preoperative chemoradiation therapy in locally advanced rectal cancer. Dis Colon Rectum 2008, 51:21-25.
23. Guillem J.G., Chessin D.B., Shia J., et al. Clinical examination following preoperative chemoradiation for rectal cancer is not a reliable surrogate endpoint. J Clin Oncol 2005, 23:3475-3479.
24. Barbaro B., Fiorucci C., Tebala C., et al. Locally advanced rectal cancer: MR imaging in prediction of response after preoperative chemotherapy and radiation therapy. Radiology 2009, 250:730-739.
25. Calvo F.A., Domper M., Matute R., et al. 18F-FDG positron emission tomography staging and restaging in rectal cancer treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 2004, 58:528-535.
26. Nissan A., Stojadinovic A., Shia J., et al. Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated with surgery alone. J Clin Oncol 2006, 24:4078-4084.
27. Green F.L., Stewart A.K., Norton H.J. New tumor-node-metastasis staging system for node-positive (stage III) rectal cancer: An analysis. J Clin Oncol 2004, 22:1778-1784.
28. Kim J.H., Beets G.L., Kim M.J., et al. High-resolution MR imaging for nodal staging in rectal cancer: Are there any criteria in addition to the size?. Eur J Radiol 2004, 52:78-83.
29. Rengan R., Paty P., Wong W.D., et al. Distal cT2N0 rectal cancer: Is there an alternative to abdominoperineal resection?. J Clin Oncol 2005, 23:4905-4912.
30. Guillem J.G., Diaz-Gonzalez J., Minsky B.D., et al. cT3N0 rectal cancer: Potential overtreatment with preoperative chemoradiotherapy is warranted. J Clin Oncol 2008, 26:368-373.
31. Mendenhall W.M., Bland K.I., Rout W.R., et al. Clinically resectable adenocarcinoma of the rectum treated with preoperative irradiation and surgery. Dis Colon Rectum 1988, 31:287-290.
32. Cercek A., Weiser M.R., Goodman K.A., et al. Complete pathologic response in the primary of rectal or colon cancer treated with FOLFOX without radiation. Proc Am Soc Clin Oncol 2010, 28:15s.
33. Rosenberg R., Maak M., Schuster T., et al. Does a rectal cancer of the upper third behave more like a colon or a rectal cancer?. Dis Colon Rectum 2010, 53:761-770.
34. Sauer R., Roedel C. The author's reply. N Engl J Med 2005, 352:510-511.
35. Nagtegaal I.D., Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer?. J Clin Oncol 2008, 26:303-312.
36. Nagtegaal I.D., van de Velde C.J.H., Marijnen C.A.M., et al. Low rectal cancer: A call for a change of approach in abdominoperineal resection. J Clin Oncol 2005, 23:9257-9264.
37. Guillem J.G., Chessin D.B., Shia J., et al. A prospective pathologic analysis using whole mount sections of rectal cancer following preoperative combined modality therapy. Implications for sphincter preservation. Ann Surg 2007, 245:88-93.
38. Branagan G., Chave H., Fuller C., et al. Can magnetic resonance imaging predict circumferential margins and TNM stage in rectal cancer?. Dis Colon Rectum 2004, 47:1317-1322.
39. Burton S., Brown G., Daniels I., et al. MRI identified prognostic features of tumors in distal sigmoid, rectosigmoid, and upper rectum: Treatment with radiotherapy and chemotherapy. Int J Radiat Oncol Biol Phys 2006, 65:445-451.
40. Rutten H., Sebag-Montefiore D., Glynne-Jones R., et al. Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma: Results of an international multicenter phase II study. Proc Am Soc Clin Oncol 2006, 24:153s.
41. Baik S.H., Kim N.K., Lee Y.C., et al. Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer. Ann Surg Oncol 2007, 14:462-469.
42. Sebag-Montefiore D., Stephens R.J., Steele R., et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): A multicenter, randomised trial. Lancet 2009, 373:811-820.
43. Marijnen C.A.M., Nagtegaal I.D., Kapiteijn E., et al. Radiotherapy does not compensate for positive resection margins in rectal cancer patients: Report of a multicenter randomized trial. Int J Radiat Oncol Biol Phys 2003, 55:1311-1320.
44. Habr-Gama A., Perez R.O., Nadalin W., et al. Operative vs. nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: Long term results. Ann Surg 2004, 240:711-718.
45. Gavioli M., Bagni A., Piccagli I., et al. Usefulness of endorectal ultrasound after preoperative radiotherapy in rectal cancer. Dis Colon Rectum 2000, 43:1075-1083.
46. Hiotis S.P., Weber S.M., Cohen A.M., et al. Assessing the predictive value of clinical complete response to neoadjuvant therapy for rectal cancer: An analysis of 488 patients. J Am Coll Surg 2002, 194:131-136.
47. Dzik-Jurask A., Domenig C., George M., et al. Diffusion MRI for prediction of response of rectal cancer to chemoradiation. Lancet 2002, 360:307-308.
48. Glynne-Jones R., Wallace M., Livingstone J.I., et al. Complete clinical response after preoperative chemoradiation in rectal cancer: Is a "wait and see" policy justified?. Dis Colon Rectum 2008, 51:10-20.
49. Borschitz T., Wachtlin D., Mohler M., et al. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer. Ann Surg Oncol 2008, 15:712-720.
50. Garcia-Aguilar J., Shi Q., Thomas C.R., et al. Pathologic complete response (pCR) to neoadjuvant chemoradiation (CRT) of uT2UN0 rectal cancer (RC) treated by local excision (LE). Results of the ACOSOG Z6041 trial. Proc Am Soc Clin Oncol 2010, 28:15s.
51. Fernandez-Martos C., Aparicio J., Salud A., et al. Multicenter randomized phase II study of chemoradiation (CRT) followed by surgery (S) and chemotherapy (CT) versus induction chemotherapy followed by CRT and S in high-risk rectal cancer: GCR-3 final efficacy and safety results. Proc Am Soc Clin Oncol 2009, 27:4103.
52. Aschele C., Pinto C., Cordio S., et al. Preoperative fluorouracil (FU) based chemoradiation with and without weekly oxaliplatin in locally advanced rectal cancer: Pathologic response analysis of the Studio Terapia Adjuvante Retto (STAR)-01 randomized phase III trial. Proc Am Soc Clin Oncol 2009, 27:804s.
53. Gerard J.P., Azria D., Gourgou-Bourgade S., et al. Comparison of two neoadjuvant chemoradiotherapy regimens for locally advanced rectal cancer: Results of the phase III Accord 12/0405 PRODIGE 2. J Clin Oncol 2010, 28:1638-1644.
54. Hofheinz R.D., von Gerstenberg-Helldorf B., Wenz F., et al. Phase I trial of capecitabine and weekly irinotecan in combination with radiotherapy for neoadjuvant therapy of rectal cancer. J Clin Oncol 2005, 23:1350-1357.
55. Rodel C., Arnold D., Hipp M., et al. Phase I-II trial of cetuximab, capecitabine, oxaliplatin, and radiotherapy as preoperative treatment in rectal cancer. Int J Radiat Oncol Biol Phys 2008, 70:1081-1086.
56. Chung K.Y., Minsky B., Schrag D., et al. Phase I trial of preoperative cetuximab with concurrent contiuous infusion 5-fluorouracil and pelvic radiation in patients with local-regionally advanced rectal cancer. Proc Am Soc Clin Oncol 2006, 24:161s.
57. van Cutsem E., Lang I., D'haens G., et al. KRAS status and efficacy in the first-line treatment of patients with metastatic colorectal cancer (mCRC) treated with FOLFIRI with or without cetuximab: The CRYSTAL experience. Proc Am Soc Clin Oncol 2008, 26:1006s.
58. Stein D.E., Mahmoud N.N., Anne P.R., et al. Longer time interval between completion of neoadjuvant chemoradiation and surgical resection does not improve downstaging of rectal carcinoma. Dis Colon Rectum 2003, 46:448-453.
59. Valentini V., Coco C., Picciocchi A., et al. Does downstaging predict improved outcome after preoperative chemoradiation for extraperitoneal locally advanced rectal cancer?. A long term analysis of 165 patients. Int J Radiat Oncol Biol Phys 2002, 53:664-674.
60. Guillem J.G., Chessin D.B., Cohen A.M., et al. Long term oncologic outcome following preoperative combined modality therapy and total mesorectal excision of locally advanced rectal cancer. Ann Surg 2005, 241:829-838.
61. Capirci C., Valentini V., Cionini L., et al. Prognostic value of pathologic complete response after neoadjuvant therapy in locally advanced rectal cancer: Long-term analysis of 566 ypCR patients. Int J Radiat Oncol Biol Phys 2008, 72:99-107.
62. Bertolini F., Bengala C., Losi L., et al. Prognostic and predictive value of baseline and posttreatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007, 68:1455-1461.
63. Unsal D., Under A., Akyuerk N., et al. Matrix metalloproteinase-9 expression correlated with tumor response in patients with locally advanced rectal cancer undergoing preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 2007, 67:196-203.
64. Johnston P.G. Prognostic markers of local relapse in rectal cancer: Are we any further forward?. J Clin Oncol 2006, 24:4049-4050.